STERIS plc (STE)

Rating: HOLD

HOLD (5-tier) · mature cash generator · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -3% vs spot
• Monte Carlo median implies -12% vs spot
• DCF fair value implies -13% vs spot
• Bear case (Structural — Reimbursement / Competition / GLP-1 Procedure Hit) downside is -57% vs spot
• Net: reward/risk of 0.2× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At $210.57 and roughly 19x forward earnings, the market prices STERIS as a steady mid-cycle sterilisation and medical-devices compounder: low-single-digit-to-mid-single-digit organic growth, a stable low-20s operating margin, and no meaningful re-rating. The engine broadly agrees. Its base path assumes 6% segment growth and a 20.5% margin, producing about 10.7 in EPS, and the five-anchor triangulation lands near $212, essentially at spot. The DCF anchor is lower at roughly $186, which caps enthusiasm: the probability-weighted target and the DCF gap together argue for HOLD rather than accumulation. Capex has held flat near $369m for four years while depreciation ran higher, so the cash-generation base is intact but not expanding. The peer-implied EV/revenue read ($270) flatters the name, yet forward-PE parity keeps us anchored. The single most damaging risk is a hospital-capex and utilisation reset: procedure and capital-equipment demand weaken together, dragging both organic growth and the multiple below the base assumption at the same time.

The dashboard below is the whole argument on one page: spot ($215) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear case is not the tail structural hit but the reset cluster: reimbursement pressure, softer hospital capital budgets, and a possible GLP-1 drag on elective procedure volumes acting together. In that path organic growth stalls toward zero and segment margin slips to roughly 18.5% as pricing and mix erode and fixed costs bite. Capital-equipment backlogs, the leading tell, roll over before consumables do, so the earnings miss arrives with a lag and lingers. Crucially, growth and multiple compress in tandem: a de-rating from ~19x toward 17x on cyclical earnings takes the target to about $155, roughly 26% below spot. With net debt of $1.65b, the deleveraging and buyback support that underpins the base multiple thins exactly when it is most needed.

Key Debate

P/E Multiple explains 60% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q2): management +0.44 vs analyst floor +0.42 → delta +0.02 (n=16 mgmt / 11 Q&A; 1th pctile across the S&P book, z -2.3).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 1000 articles): avg ticker sentiment +0.24 (bullish 32% / bearish 1%)

Scenario Analysis

The tree runs from a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($94) to a 'Bull — Re-Rate' bull case ($366); the probability-weighted blend (PWEV $210) is -3% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $94). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 93.13; probability: 0.2.
• Hospital-Capex / Utilization Recession (17%, $155). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising. Drivers — implied_target: 158.15; probability: 0.17.
• Base — Procedure Volume + Innovation (35%, $220). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns. Drivers — implied_target: 219.66; probability: 0.35.
• Growth — New-Product Cycle / Penetration (20%, $294). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 296.54; probability: 0.2.
• Bull — Re-Rate (8%, $366). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration. Drivers — implied_target: 374.51; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $190 and 38% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (60% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 16x terminal FCF multiple → $187. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 19.03x) implies $212. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 40% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Devices Tools

This name sits in the Health Devices Tools as a medical_devices. procedure volumes + product-innovation cycle + hospital capital spending Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: TMO (life_science_tools) · ABT (medical_devices) · ISRG (medical_devices) · DHR (life_science_tools) · SYK (medical_devices) · MDT (medical_devices) · BSX (medical_devices) · EW (medical_devices) · IDXX (animal_health) · BDX (medical_devices) · A (life_science_tools) · WAT (life_science_tools) · ZTS (animal_health) · IQV (life_science_tools) · GEHC (medical_devices) · RMD (medical_devices) · DXCM (medical_devices) · VEEV (life_science_tools) · MTD (life_science_tools) · WST (medical_devices) · STE (medical_devices) · ZBH (medical_devices) · COO (medical_devices) · SOLV (medical_devices) · ALGN (medical_devices) · RVTY (medical_devices) · BAX (medical_devices) · PODD (medical_devices) · CRL (life_science_tools) · TECH (life_science_tools)

Mapping note: name-level 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' (20%) + 'Hospital-Capex / Utilization Recession' (17%) map to cluster Reimbursement / Funding / Utilization Reset (37%); name-level 'Growth — New-Product Cycle / Penetration' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Innovation / Recovery Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Funding / Utilization Reset () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The health_devices_tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $5B + PV(terminal) $15B = EV $20B; + net cash → equity $18B ÷ diluted shares 0.10B = $187/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $197/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 15% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $212; EV/Rev → $270.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Medical Devices & Equipment multiple (AI re-rating) (base 19x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2026-03-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1.1% of revenue; cash conversion (OCF/NI) 171% — cash-backed.

Catalyst Calendar

• 2026-08-05 (~28d) — Quarterly earnings — est. EPS $2.52 (AV EARNINGS_CALENDAR)
• 2026-09-20 (~74d) — EtO / sterilant regulatory (EPA/FDA) decision on ethylene-oxide emissions (authored)
• 2026-11-05 (~120d) — Capital-equipment order-backlog trend disclosure (authored)
• 2027-05-10 (~306d) — Full-year (FY ending March) adjusted EPS guidance (authored)

Forecast Track Record

• EPS surprise: beat 62.5% of the last 8 quarters; average surprise +1.9%.

Competitive Moat

Wide moat. Leadership in infection prevention and sterilisation with a razor/blade consumables-and-service annuity and high hospital switching costs supports a terminal multiple above the market; the falsifiable claim is that if organic constant-currency growth stalls below ~3% and segment margin slips under 19.5% for two years, the moat is only narrow and the terminal multiple should compress toward the ~17x cyclical anchor from the ~20.5x base.

Moat sources:

• Installed base of sterilisation/endoscopy equipment pulling recurring consumables and service
• Outsourced sterilisation network (Applied Sterilization Technologies) with scale and regulatory barriers
• Validated hospital workflows and switching costs on infection-prevention protocols
• Regulatory (FDA/EPA) barriers on sterilant chemistries and reprocessing

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 17.7× forward EPS, vs the house DCF terminal 16.0×, and a peer median 19.03×. The house DCF sits 13% below spot, so the market is pricing in more than the house case — roughly 1.4pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 19.8× (simple median 19.03×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $195–$268, centre $228 (+6% vs spot); spot sits at the 28th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Re-Rate): $366.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (56.0); Revenue CAGR ±3pp (53.0); Terminal × ±15% (46.0); Capex intensity ±15% (19.0); WACC ±1pp (17.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 16×, FY+5 revenue $8B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic constant-currency revenue growth < 0.03 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Base assumes ~6% segment growth. Organic growth stalling below 3% for two quarters would signal the hospital-capex / utilisation recession path is materialising, not the mid-cycle base.
• Segment operating margin < 0.195 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Base margin is 20.5%; the cyclical path sits at 18.5%. Margin printing below 19.5% for two quarters would confirm pricing and mix pressure ahead of the base assumption.
• Full-year adjusted EPS guidance revision < 10.0 (single event → Reimbursement / Funding / Utilization Reset). Base-path EPS is ~10.7. A guided full-year adjusted EPS floor cut below 10.0 at any print would move the weighting toward the cyclical / structural cluster.
• Capital-equipment order backlog change < 0.0 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). Healthcare capital-equipment demand is the leading tell for hospital-capex weakness. A backlog contracting year-on-year for two quarters would front-run a utilisation reset before it hits consumables.
• Trailing free cash flow (operating cash flow minus capex) < 0.8 (2 consecutive prints → Reimbursement / Funding / Utilization Reset). FY2026 delivered ~$0.97b FCF (OCF $1.34b less capex $0.37b). Annualised FCF dropping below $0.8b while capex holds would compress the shareholder-return and deleveraging case that supports the base multiple.

Fact / Inference / Speculation

• FACT: Spot $215; 52-week range $195–$268; engine rating HOLD; base-case target $212 (-2%). (source: Alpha Vantage 2026-06-27, 8 July 2026)
• INFERENCE: Triangulated FV $197 (-9% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Recommendation: HOLD

Balanced: triangulated fair value $197 (-9% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.